Key points
- Final results of pivotal Alzheimer's trial expected in November 2026
- Completed manufacture of additional Xanamem tablets for open-label extension
- Strengthened intellectual property with new patent filings
Full summary
Actinogen Medical Ltd, an ASX-listed biotechnology company, has released its 2026 annual report, detailing financial results and updates on its clinical trials for Xanamem, a novel therapy for Alzheimer's disease. The company reported a net loss of $15.4 million for the year ended June 30, 2026, compared to a loss of $14.7 million in the previous year. The XanaMIA Phase 2b/3 Alzheimer's disease trial, which is fully enrolled with 247 patients, is on track for topline results in November 2026. An open-label extension phase has commenced, with 89% of participants from the main trial moving into this phase. The company has also completed the manufacture of additional Xanamem tablets for the open-label extension. Actinogen has strengthened its intellectual property with new patent filings covering Xanamem's treatment of cognitive decline in healthy elderly people and key manufacturing steps.
Guidance
Final results of pivotal Alzheimer's trial expected in November 2026
Outlook
The company is focused on advancing Xanamem in Alzheimer's disease and other neurological indications, with the potential for additional therapeutic approaches in the future.